Twist partners with Lilly AI platform

• Twist Bioscience agreed to provide antibody characterization data services for Lilly TuneLab.
• The partnership connects laboratory data with AI models for antibody drug discovery.
• Researchers will use Twist protocols to generate data for Lilly’s AI/ML discovery platform.

Twist Bioscience (NASDAQ:TWST) entered an agreement with Lilly TuneLab, an artificial intelligence and machine learning drug discovery platform created by Eli Lilly (NYSE:LLY), to provide antibody characterization data services.

The collaboration will support TuneLab’s antibody developability prediction model by connecting high-throughput laboratory data from Twist with AI-driven drug discovery tools.

Under the agreement, TuneLab users will be able to order antibody services from Twist using preferred protocols to generate laboratory data that can support candidate selection and AI model training.

Twist said its high-throughput antibody characterization capabilities are designed to provide consistent data for AI models used in drug discovery research.

Twist Bioscience develops synthetic DNA technologies and provides research services for biotechnology, pharmaceutical, and other scientific applications.

Lilly TuneLab is part of Lilly Catalyze360, which provides biotech companies with access to technology, research capabilities, and other resources supporting drug development.